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Abstract
Despite the increasing number of potential biomarkers identified in laboratories and reported in much literature, the adoption 
of biomarkers routinely available in clinical practice to inform treatment decisions is very limited. Reimbursement decisions 
for new health technologies are often informed by economic evaluations; however, economic evaluations of diagnostics/test-
ing technologies, such as companion biomarker tests, are far less frequently reported than drugs. Furthermore, few countries 
provide the health economic evaluation methods guide specific to co-dependent technologies such as companion diagnostics 
or precision medicines. Therefore, this paper aims to guide the process of the development of cost-effectiveness models of 
cancer biomarkers for targeted therapies, focusing on companion diagnostics. This tutorial paper provides practical guidance 
on how to conduct economic evaluations of cancer biomarkers and how to model the characteristics of the biomarker tests 
as part of the value for money of corresponding targeted therapies. This paper presents a brief introduction to the methods 
and data requirements, a step-by-step guide to constructing a health economic model of companion cancer biomarkers, and 
a discussion of issues that arise in their application to healthcare decision making. This practical guidance is provided in 
R, and worked examples are provided in this paper with R codes in the accompanying electronic supplementary material.
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1 Introduction
The optimization of treatment strategies has become possi-
ble based on the information provided by biomarkers before 
the administration of treatments, especially in oncology. 
This advance has raised expectations over biomarker-guided 
therapies in cancer that may improve patient outcomes while 
helping to achieve efficient resource allocation in health-
care [1–5]. However, the number of biomarkers successfully 
entering clinical routine practices is very low compared with 
the number of biomarkers published [6, 7]. One argues that 
the lack of consensus in methodological approaches and data 
requirements in economic evaluations of biomarkers might 
be one of the limiting factors on why there are as yet only a 
small number of biomarker tests routinely provided in clini-
cal practice [8–10]. Furthermore, few countries provide a 
guide to the methods of health economic evaluation spe-
cifically for co-dependent technologies; only two countries 
(Australia and Scotland) provide some high-level guidance 
on modeling the characteristics of companion testing tech-
nologies as part of assessing the value for money of co-
dependent technologies such as biomarker-guided therapies 
or companion diagnostics [11, 12]. It reflects the current 
reality that reimbursement agencies in many countries do 
not keep pace with the rapidly evolving health technolo-
gies such as ‘omics’-based therapies with the integration of 
companion biomarkers.
This tutorial paper aims to guide the process of the devel-
opment of cost-effectiveness models of companion cancer 
biomarkers for targeted therapies (specifically companion 
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Key Points for Decision makers 
No clear methods guidance exists on how to model com-
panion testing technologies as part of economic evalu-
ations of biomarker-guided therapies. Few countries 
provide the health economic evaluation methods guide 
specific to co-dependent technologies such as companion 
diagnostics and biomarker-guided therapies.
This tutorial article provides a step-by-step guide on 
constructing a health economic model to assess the value 
for money of biomarker-guided therapies. A core model 
was developed as part of the worked examples of this 
tutorial, using R. Users can readily adapt the core model, 
with appropriate adjustments to data inputs and model 
structure.
This tutorial can also inform users of relevant data inputs 
of companion biomarker tests required to incorporate 
in economic evaluations of biomarker-guided therapies 
before designing studies/trials for data collection.
We chose to use R (The R Foundation for Statistical Com-
puting, Vienna, Austria) in building this practical model 
because of the advantages of using R (or script-based pro-
gramming) for the development of economic models for 
health technology assessment (HTA), although these are 
only beginning to be recognized [15]. R is easily reproduc-
ible and flexible compared with Microsoft Excel® (Micro-
soft Corporation, Redmond, WA, USA).
2  Model Background and Description
Overall, several elements need to be defined in order to con-
struct the health economic model for health technologies. 
The decision problem of this tutorial is to assess the cost 
effectiveness of testing patients with a companion biomarker 
test and treating them according to their biomarker status, 
in comparison with comparator strategies such as treat 
all patients with the biomarker-guided therapy or treat all 
patients with usual treatment regardless of biomarker status 
without testing. The study design is a model-based cost-
effectiveness analysis using a hypothetical cohort of patients, 
and the study outcome to be calculated is incremental cost-
effectiveness ratio (ICER; cost per life-year [LY] and cost 
per quality-adjusted life-year [QALY] gained). The reference 
case applied in this worked example of the core model is 
summarized in Table 1. This core model is developed based 
on the findings and practical lessons acquired from previ-
ous studies on companion diagnostics or co-dependent tech-
nologies [8, 10, 16, 17]. Systematic reviews found that the 
characteristics of companion biomarker tests were not con-
sistently incorporated in economic evaluations of biomarker-
guided therapies and the structure of comparative analyses 
of the strategy arms was so varied that it may lead to a differ-
ent conclusion in terms of cost effectiveness [8, 10, 17]. The 
process of building a health economic model involves defin-
ing the structure of the model and data inputs. Its detailed 
descriptions are provided in the following subsections.
2.1  Strategy Arms to be Compared and Assessed
The intervention strategy of this core model is biomarker-
guided therapies guided by companion diagnostics that 
patients are tested prior to the administration of targeted 
therapies according to their biomarker status (Table 1). In 
terms of comparator strategy that this intervention strategy 
is being compared against, standard of care (SOC) is an 
appropriate comparator strategy that reflects the most rel-
evant alternative intervention(s) used in clinical practice [18, 
19]. However, previous literature reviews [8, 10] found that 
the existing literature of economic evaluations demonstrates 
that the choice of comparator strategies and the comparison 
structure is not consistently applied in economic evaluations 
diagnostics, classifying patients into responders and non-
responders for a specified therapeutic agent in treating 
patients with cancer). Companion biomarker tests (inter-
changeably, companion diagnostics) guide the safe and 
effective use of therapeutics with its approved label restrict-
ing drug access [13]. Although model conceptualization 
is the first key step in developing an appropriate model, 
it is beyond the scope of this tutorial paper. This paper is 
intended for those who chose a state-transition model as 
their appropriate model, based on their decision problems to 
be represented in the model. For those who are not yet clear 
what model types are appropriate for their decision prob-
lems, there is a useful paper providing a series of consensus-
based best practices for the process of model conceptualiza-
tion [14]. For example, when the decision problem requires 
modeling the effect of patient interaction (e.g. the treatment 
effect on disease spread), this core model is not applica-
ble. As explained by Roberts et al. [14], this state-transition 
model is appropriate in instances where the disease is broken 
into distinct health states, as in cancer.
Users can adapt this core model to assess their biomarker-
guided therapies by making local adaptations in data require-
ments and methodological approaches from the perspective 
of their specific payers and country settings. The example 
used in this tutorial paper has three health states, progres-
sion-free survival (PFS), progressive disease (PD), and dead. 
This analysis is performed for a hypothetical cohort of can-
cer patients who are not eligible for tumor excision surgery.
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of biomarker-guided therapies. For example, SOC (e.g. 
usual therapy without biomarker testing) was not chosen 
as a comparator strategy in some evaluations. Instead, they 
compared biomarker-guided therapy with biomarker testing 
versus without the testing, while no SOC was considered 
in the evaluations. Therefore, based on the study findings 
from previous studies [8, 10, 16], we found that assessing 
the biomarker-guided therapy against two comparator strate-
gies was the most suitable structure for strategy comparison. 
Therefore, we constructed three strategies as default com-
parisons in this core model: (1) patients being tested with 
a companion biomarker and treated with the corresponding 
targeted therapy according to their biomarker testing result 
(hereinafter referred to as the test–treat strategy, i.e. ‘TT 
arm’); (2) patients not tested and treated with SOC (here-
inafter referred to as the usual care strategy, i.e. ‘all-UC 
arm’); and (3) patients not tested and treated with the cor-
responding targeted therapy (hereinafter referred to as the 
targeted care strategy, i.e. ‘all-TC arm’). These arms can be 
compared with one another depending on the decision prob-
lem, and the users are expected to adapt this core model for 
their specific research question. This construct of compara-
tive strategy arms is also line with what has been suggested 
by previous studies [17, 20]. The detailed schematic of the 
comparative structure of strategy arms is depicted in Fig. 1.
2.2  Model Structure
A discrete-time Markov cohort model is constructed to 
record the transition between health states experienced by a 
hypothetical cohort of patients eligible to be treated either 
with targeted care (biomarker-guided therapy) or usual 
care (non-guided therapy) in oncology treatments. Health-
related quality of life (HRQoL) weights and a cost pertinent 
to each of these health states are assigned. The model has 
three mutually exclusive health states: PFS, PD, and dead. 
As depicted in Fig. 2, the arrows indicate the flow of indi-
vidual patients in every model cycle. Transition from PD to 
PFS is assumed to be impossible. The transition probability 
can be calculated using the formula suggested by Briggs 
et al. [21]. Given that health states are mutually exclusive, 
the transition probabilities sum to one. A Markov model 
of disease progression is presented in Fig. 2. The detailed 
model schematic of decision tree linking to the health state 
transitions is provided in Fig. 1, with ‘M’ indicating a move 
into the Markov model. Once patients are allocated to their 
respective decision branch, they enter a Markov model based 
on their assigned transition probabilities. Patients assigned 
to ‘treat-all’ strategies (either with new therapy or with usual 
therapy) will enter the Markov model without being bio-
marker tested, and move to respective health states (PFS, 
PD, dead) assigned by the given transition probabilities. On 
the other hand, patients assigned to the ‘test–treat’ strategy 
arm will be either provided new therapy or usual therapy 
according to biomarker status, and will then enter a Markov 
model and be assigned to a respective health state followed 
by transition probabilities. A lifetime horizon is applied.
2.3  Data Requirements and Model Inputs
Model inputs are detailed in Table 2. These data inputs 
are just exemplary figures to guide the process of develop-
ing an economic model for biomarker-guided therapies, 
developed based on the previous study findings [8, 10, 16]. 
For example, we have incorporated all data inputs relevant 
to the key characteristics of companion biomarker tests 
that are often ignored in existing economic evaluations of 
biomarker-guided therapies such as clinical utility, patient 
preferences (disutility or utility of biomarker testing), 
frequency/prevalence of biomarker status, and diagnostic 
Table 1 Summary of the reference case used in this guide
Element Reference case
Intervention strategy Test–treat patients according to biomarker status, using companion diagnostics for targeted therapies
Choice of treatment alternative (compara-
tor strategies)
The comparator strategy that the new biomarker-guided therapy will most likely replace. Thus, in 
this core model, two comparator strategies were employed: (1) Treat all patients with biomarker-
guided therapy regardless of biomarker status; (2) Treat all patients with usual treatment regard-
less of biomarker status
Health state Three health states: progression-free survival (PFS), progressed disease (PD) and dead
Viewpoint of the analysis Health system perspective
Time horizon Lifetime
Analysis model Cost-utility analysis
Health outcome Quality-adjusted life-year
Method for the measurement and valua-
tion of health effects
Generic measures of health instruments
Discounting rate 3.5%
Uncertainty Probabilistic sensitivity analysis; with an option of deterministic sensitivity analysis
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accuracy, including false negative and false positive. A 
third-party payer perspective (e.g. the National Health 
Service) is employed in developing the model, and thus 
any non-medical costs (e.g. lost productivity costs) are 
beyond the scope of this core modeling practice. Health 
state costs are defined per model cycle, including drug 
costs and biomarker testing costs (Table 2). HRQoL (e.g. 
EQ-5D) data inputs are also provided in Table 2. In prac-
tice, HRQoL data are often obtained along with clinical 
trials or by separate literature reviews (e.g. systematic 
literature review and/or meta-analysis); however, for the 
development of this practical guide, dummy estimates on 
utility values are used in this core model, although these 
data are obtained by clinical trials or separate literature 
reviews in practice. It is recommended that all relevant 
data from difference sources (e.g. clinical trials) are sys-
tematically synthesized and incorporated in economic 
evaluations [22, 23]. Biomarker-related parameters such as 
biomarker testing disutility value, performance accuracy 
(sensitivity and specificity), and biomarker prevalence are 
also shown in Table 2. Companion diagnostic technology 
for cancer patients usually require collecting a biosample 
for analysis, and this gives rise to the existence of pro-
cess utility (such as reassurance or information) [24–26]. 
Patients might express different preferences by being 
informed of the process of interventions or diagnostics; 
for example, patients may prefer diagnostic A because it 
is more convenient or informative to them than diagnostic 
B, even though there is no definite difference in health 
outcomes. Brennan and Dixon supported the existence of 
process utility and found different approaches being used 
to detect and measure it [27]. Given the existence of pro-
cess utility, in this core model, testing disutility was used 
under the assumption that undergoing biomarker testing 
might cause some discomfort to patients. However, if this 
is not the case (e.g. testing bringing not discomfort but 
convenience to patients), the utility value of testing should 
be considered when adapting this core model. In addition, 
transition probabilities, drug efficacy, and discounting rate 
are also provided. All-cause mortality was not considered 
in this core model, however it should be considered when 
adapting this core model for local adaptations of country-
specific settings. In other words, modellers are advised to 
incorporate country-specific epidemiological data, such 
as all-cause mortality, into the core model for their local 
adaptations if applicable.
2.4  Uncertainty Analysis
Uncertainty analysis is a standard practice in modeling 
studies to assess the uncertainties around parameters 
and assumptions used in the model. Both deterministic 
sensitivity analyses (DSA) and probabilistic sensitivity 
analyses (PSA) are performed in this practical model in 
order to assess the impact of parameter uncertainty on the 
cost-effectiveness results. DSA is performed to test the 
sensitivity of the results of cost effectiveness to specific 
parameter values. As for PSA, all parameters are simul-
taneously tested for uncertainty while randomly sampling 
Fig. 1  Model schematic. ‘M’ 
indicates a move into the Model 
in Fig. 2. PFS progression-free 




Fig. 2  Health transition diagram. PFS progression-free survival, PD 
progressed disease
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the parameter values from a priori-defined probability 
distributions [28].
3  Step‑by‑Step Guide
Figure 3 is an overall picture of the steps involved to perform 
cost-effectiveness analysis of companion biomarkers for tar-
geted therapies in R. Note that it is a general guidance and 
thus some specific adjustments might be required depending 
on the country-specific clinical settings or country-specific 
HTA requirements. It should also be decision problem spe-
cific. An explanation of each step is provided. More detailed 
R codes are provided in electronic supplementary material 
(ESM) 1–7. R codes can be self-explanatory, with some 
notes written in italics with the # symbol, which can be use-
ful when the codes are copied and pasted in R; however, a 
basic understanding of R is required in order to follow this 
guide. This modeling guide is not intended for complete R 
beginners. As a basic note, the <- symbol is to assign values 
in R.
3.1  Step 1: Create Transition Probability Matrices
This step is to prepare the transition probability matrix per 
strategy arm. Before this step, it is necessary to first decide 
which model is suitable, such as a Markov or semi-Markov 
model, etc., as shown in Fig. 1. The core model presented 
here is constructed based on a state-transition model. In 
order to construct the probability matrices, parameter val-
ues exampled in Table 2 need to be assigned to R first. It 
can then create the transition matrix of each health state 
per strategy arm. Refer to ESM 1 for the entire R code for 
Step 1.
Table 2  Parameter values for the model development
PFS progression-free survival, PD progressed disease
Variable name coded in R Value Description
Costs
cPFS 500 State cost of one cycle in the progression-free disease state
cPD 3000 State cost of one cycle in the progressive disease state
cDrug 1000 State cost of drug for one cycle
cTest 100 State cost of biomarker testing for one cycle
cDead 0 State cost of one cycle in the death
Quality-of-life adjustments
uPFS.UC 0.75 Quality-of-life weight for one cycle in PFS for patients treated with usual care
uPD.UC 0.65 Quality-of-life weight for one cycle in PD for patients treated with usual care
uPFS.TC 0.80 Quality-of-life weight for one cycle in PFS for patients treated with targeted care
uPD.TC 0.70 Quality-of-life weight for one cycle in PD for patients treated with targeted care
Biomarker-related parameters
disutility.Test 0.05 Disutility value of testing a biomarker status
pBiomarker 0.74 Biomarker prevalence/frequency
tp 0.285 Biomarker testing accuracy (true positive)
fp 0.245 Biomarker testing accuracy (false positive)
tn 0.015 Biomarker testing accuracy (true negative)
fn 0.455 Biomarker testing accuracy (false negative)
Transition probabilities
pPFS2PD 0.2 Probability of entering the PD state
pPD2D 0.25 Probability of dying from PD
pPFS2D 0.05 Probability of dying from PFS
pPD2PFS 0 Recovery from PD to PFS is not permitted in the model
Other parameters
eff 0.25 Targeted drug reduces the likelihood of being progressed by 25% Relative risk 
of disease progression from using the drug
Targeted drug is discontinued upon progression
rDiscount 0.035 Discount rate for outcomes and costs 3.5%
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3.2  Step 2: Create Cost and Utility Transition 
Matrices
Similarly, the transition matrices for cost and utility values 
can be prepared using the Matrix command in R. This step 
is similar to Step 1 in a sense that model inputs are defined 
and vectored into the R model. The detailed R code for Step 
2 is provided in ESM 2.
3.3  Step 3: Building a Markov Model for the ‘All 
Usual Care’ Arm
Based on the transition matrices set up in Step 1, a Markov 
trace with a hypothetical cohort of patients, summing up 
over time, needs to be constructed. In this stage, all different 
scenarios of treatment pathways by different strategy and 
testing results should be constructed, as depicted in Fig. 1 
and Fig. 2. Thus, biomarker-related data need to be defined 
and vectored into the R model including biomarker testing 
accuracy and biomarker prevalence. Overall, 1000 cycles 
were assigned to capture the lifetime horizon of all patients 
entered in the model, with one cycle being equivalent to 
1 month in this core model. In other words, 1000 cycles are 
equivalent to 83.33 years, which is long enough to simulate 
the model in a lifetime horizon. Depending on the progres-
sion of the disease of interest, the cycle can be shortened 
or lengthened. These model settings can be easily altered 
according to local adaptation requirements. The R code for 
this Step 3 is detailed in ESM 3.
3.4  Step 4: Adapting the Model for the ‘All Targeted 
Care’ and ‘Test–Treat’ Arms
This stage is relatively simple. The R code used for the 
all-UC arm in Step 3 can be easily modified and adapted 
for both the all-TC and TT arms. This feature is one of the 
advantages of using a script-based program when build-
ing health economic models. It can be easily transformed 
and adapted for other strategy arms with a relatively small 
amount of time and effort dedicated. The cohort trace of 
patients in the all-TC arm needs to be separated into two 
branches depending on their actual biomarker status, 
because all patients will be treated with biomarker-guided 
therapy; however, some patients might not be biomarker-
positive and thus the targeted therapy will not be effective 
for these patients. The cohort trace for patients in the TT 
arm needs to be separately constructed for patients who truly 
tested positive, falsely tested positive, truly tested negative, 
or falsely tested negative. Cohort simulation commences 
with a hypothetical cohort of patients (in this core model, it 
is set at 1000, which means a hypothetical cohort of 1000 
patients started the model). These patients then move or 
stay in the possible health state according to the transition 
probabilities defined by different treatment scenarios of the 
strategy arms. The simulation tracks the cohort from one 
cycle to the next following the transition probabilities. Refer 
to ESM 4 for the detailed R code for Step 4.
3.5  Step 5: Computing Epidemiological Outcomes
Epidemiological outcomes of different health states can be 
computed and plotted in a graph using the R code written 
in ESM 5. Respective cohort traces per strategy arm can be 
plotted as survival curves. For the all-TC and TT arms, the 
cohort transition matrices need to be merged before plotting 
the survival curves. Overall survival (OS) probability can be 
separately computed and plotted in the OS curve according 
to different strategy arms. Life expectancy can be calculated 
by summing the probability of OS over time.
3.6  Step 6. Estimating the Base‑Case Cost 
Effectiveness
We are now ready to perform the analysis and estimate the 
expected values and cost effectiveness. In R, the expected 
values of each strategy can be calculated by processing the 
multiplication of the Markov trace produced in Steps 3 and 
4 and the transition matrices of the cost and utility inputs 
Vectoring model inputs   
Construc ng transi n matrices (probability, costs, u lity values) 
Building a Markov model for all UC strategy arm    
Adap ng all-UC model for all-TC and Test-Treat arm respec ly    
Compu ng epidemiological outcomes    
Es ma ng the basecase cost-effec ness     
Performing sensi ty analyses     
Choice of modelling approach 
Fig. 3  Algorithm steps in performing cost-effectiveness analysis for 
cancer biomarkers for targeted therapies in R. UC usual care, TC tar-
geted care
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produced in Step 2. The R code for Step 6 is provided in 
ESM 6, with self-explanatory comments shown in italics. 
The example base-case ICER calculated for this exercise is 
also provided in ESM 6.
3.7  Step 7: Performing Sensitivity Analyses
Uncertainty analysis is a standard practice in modeling 
studies to assess the uncertainties around parameters and 
assumptions used in the model. ESM 7 explains how to 
perform PSA using R as an integral part of the uncertainty 
analysis of cancer biomarkers for targeted therapies in addi-
tion to the detailed R code. In R, the model can be run by the 
function defined by the modeler (R is known to be extremely 
flexible in this regard) and we define all parameters in the 
run_model function. DSA modeling is similar to that of PSA 
(refer to the supplementary R code for DSA in ESM 7).
In addition to this parameter uncertainty, an analysis of 
structural uncertainty can be performed by adapting this 
core model. For example, the structure of health states can 
be readily altered considering the natural course of disease 
progression of interest for local adaptation.
4  Discussion
This paper introduced a core model that can be adapt-
able for users’ analysis of their specific datasets and 
requirements in assessing the value of cancer biomark-
ers. This guide demonstrated the model structure of 
strategy comparisons and data requirements relevant to 
the characteristics of companion biomarker testing that 
require incorporation into the health economic modeling 
of biomarker-targeted therapies. Users can vector in their 
specific data inputs instead of dummy variables used in 
the worked example (Steps 1, 2 and 3). In addition, those 
wanting to make any structural changes, such as health 
states or strategy arms, can readily replicate the process 
of creating the transition matrices by modifying (adding/
removing) the matrices of transition probability, cost, and 
utility values in Steps 1–2. Nevertheless, we expect the 
user to have a prior understanding of, and experience with, 
R coding in order to understand this tutorial and adapt 
this core model for their specific local model. For any 
beginners using R, there are useful references to familiar-
ize themselves first [29, 30]. For those who need a more 
generic understanding on health economic modeling in R 
that is non-specific to certain health technologies, such as 
companion biomarker tests as focused on in this tutorial, 
a tutorial paper is available that they might like to read 
first [31].
As found in a previous study [10], many existing eco-
nomic evaluations of biomarker-guided therapies have 
ignored several key characteristics of companion bio-
markers when assessing the value for money of biomarker-
guided therapies. They found that the most frequently 
ignored areas were patient preferences, clinical utility, 
and prevalence of biomarker status, while the costs of 
biomarker testing were considered. For example, it can 
be very difficult to generate data inputs on the clinical 
value of companion biomarker tests if the biomarker test 
is developed in silos without being embedded in the clini-
cal trials of its corresponding drug. This tutorial informs 
readers on what key data inputs relevant to companion 
biomarker tests are required to be incorporated and tested 
for uncertainty in economic evaluations of the guided 
therapies.
Furthermore, given that a single clinical study is 
unlikely to include all relevant scenarios of the TT, all-
UC and all-TT arms, data synthesis from multiple sources 
might be more challenging for co-dependent technolo-
gies (i.e. biomarker-guided therapies) than traditional 
health technologies. Nevertheless, it is widely known that 
all relevant data from different sources of clinical trials 
should be systematically synthesized and incorporated in 
economic evaluations. When direct evidence (i.e. head-to-
head trials) is lacking, network meta-analysis or indirect 
treatment comparison methods are useful to synthesize 
the estimates of clinical trials. These methods of data 
synthesis for economic evaluations are beyond the scope 
of this tutorial and have been described extensively else-
where, including uncertainty analyses around the impact 
of synthesis-based estimates on cost effectiveness [18, 22, 
23, 32, 33].
This paper has also provided a step-by-step guide to car-
rying out cost-effectiveness analysis for biomarker-guided 
therapies in the state-transition modeling framework, and 
has provided R codes in vectoring data inputs, running the 
simulations, performing survival analyses, calculating base-
case mean LYs/QALYs and performing sensitivity analyses. 
The user can adapt this core model to develop their own 
local model applied to their specific cancer biomarker test-
ing technology and specific jurisdiction of reimbursement 
decision making. Alternatively, test developers can assess 
the potential value for money of their candidate cancer bio-
marker tests at an early stage of development by incorporat-
ing the pertinent model inputs with necessary adaptations 
and modifications to this core model. For example, the user 
can adapt the structure of health states, the strategy arms to 
be compared against one another, transition probabilities, 
biomarker-specific characteristics, and cost and utility val-
ues, etc. However, for those who need to reconstruct time-
to-event data from published Kaplan–Meier survival curves 
as part of building health economic models in R, two useful 
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tutorial papers providing algorithms are available for the 
user to use [34, 35].
There are a couple of limitations that readers might wish 
to take into consideration when adapting this model for their 
local models. First, this core model is constructed based on a 
state-transition model and therefore, those wishing to build 
a partitioned survival model (PSM) may require more time 
to adapt. However, PSM does not require as many of the 
modeling techniques as used in the state-transition model. 
Second, the user is required to have some understanding of 
the concepts of economic evaluations and HTA, as well as 
knowledge of programing in R. Therefore, there is still a 
programing language barrier for test developers to adapt or 
apply this core model to their data and requirements if the 
user is not familiar with cost-effectiveness analysis and R 
coding. It requires some intermediate level of R program-
ing/coding and a conceptual understanding of economic 
evaluations of health technologies. Third, guiding on how 
to validate a model was not covered by this guide because 
this study intends to provide a step-by-step guide on how to 
build a model of co-dependent technologies rather than pro-
viding a guide to the validation of a specific model. Further-
more, this core model is built using ‘exemplary’ data inputs 
(not real dataset) and thus, as Eddy et al. suggested in the 
model validation [36], the concept of validity should apply 
to particular applications, not to the model itself. Therefore, 
modellers wishing to adapt this core model to their local 
settings with a specific dataset (e.g. ‘real’ data inputs from 
clinical trials) and assumptions applied to their specific deci-
sion problems, the process of model validation should be 
accompanied in their local adaptation model. Several guid-
ances and checklists have been published on good practices 
of model validation [36–38].
A couple of areas can be recommended for further devel-
opment of this core model. First, although the R codes pro-
vided in this guide are verified by running the model in R, 
it was not tested to what extent this model can be applicable 
to actual datasets. By applying this core model to the pub-
lished economic evaluations of biomarker-guided therapies, 
the generalizability of this model can be further validated. 
By doing so might give more insights into how and under 
what circumstances this core model is adaptable, difficult 
to adapt, or unadaptable at all. Second, this core model can 
be further developed to make it easily accessible to those 
unfamiliar with R. For example, the model can be further 
developed to user-friendly, interface, web-based applications 
using the Shiny R package, as undertaken by Strong et al. in 
assessing the value of information [39].
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